Table 2.
Nonnucleoside Reverse Transcriptase Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Drug-Resistant Mutations and Individual Patient Demographics
| Patient ID | NRTI | NNRTI | CD4 | Viral load |
|---|---|---|---|---|
| <2 years | CD4% | |||
| 1 | M184V | A98G, K101E, Y181C | na | 336,845 |
| 2 to <5 years | CD4% | |||
| 2 | M184V, T215F | V108I, Y181C | na | 2,710,000 |
| 3 | D67DN, M184V | A98G, Y181C | 19 | 21,393 |
| 4 | D67N, M184V | K103N | na | 33,244 |
| 5 | M184V | K101E, G190A | 32 | 35,037 |
| 6 | M184V | K101E, Y181C | na | 37 |
| 7 | M184V | K103N, V108I | 32 | 51,860 |
| 8 | M184V | Y181C | 20 | 591,096 |
| ≥5 years | CD4 count | |||
| 9 | A62V, D67N, V75I, F77L, F116Y, Q151M, M184V | K101E, G190A | 549 | 58,287 |
| 10 | D67N, K70R, M184V, T215F, K219E | A98G, V108I, Y181C | na | 32,990 |
| 11 | M41L, D67N, M184V, L210W, T215Y | V106I, G190A | na | 786,933 |
| 12 | A62V, V75I, F116FY, Q151M, M184V | E138G, G190A | 701 | 267,409 |
| 13 | D67N, M184V, L210W, T215F | K101E, G190S | 380 | 69,149 |
| 14 | D67N, F77FL, F116Y, Q151M, M184V | Y181C | 878 | 14,940 |
| 15 | A62V, M184I, L210W, T215F | V90I, Y181C | 856 | 87,104 |
| 16 | D67N, M184V, T215Y | K101E, G190A | 423 | 57,093 |
| 17 | M41L, K65R, M184V | V106I, Y181C | 1,018 | 227,554 |
| 18 | V75IV, F116Y, Q151M, M184V | K103N | 422 | 27,274 |
| 19 | K65R, F116Y, Q151M | K103N, Y181C | 130 | 1,070,000 |
| 20 | M41LM, M184V | V106I, Y181CY, G190AG | 758 | 11,085 |
| 21 | M184V | K103N, V106I, V108I, V179IT | 1,042 | 0 |
| 22 | A62V, V75I, M184V | Y181C | na | 16,347 |
| 23 | K70KR, M184V | K103N, Y181C | 727 | 7,448 |
| 24 | K65R, D67N | Y181C, G190A | 321 | 101,467 |
| 25 | V75I, M184I | V108I, Y181C | 1,383 | 400 |
| 26 | M184V, T215F | V108I, Y181C | 332 | 42,378 |
| 27 | M41LM, V75I, M184V | G190A | 2,236 | 9,533 |
| 28 | D67DN, M184V | V90I, Y181C | 820 | 400 |
| 29 | M184V, T215Y | V106IV, Y181C | 225 | 112,223 |
| 30 | D67N, M184V | V106I, Y181V | 644 | 7,605 |
| 31* | M184V | K103N, V106I, M230L | 818 | 3,627 |
| 32 | M184V | V108I, Y181C | 1,274 | 250 |
| 33 | D67DN, M184V | Y181C | 971 | 95,874 |
| 34 | D67DN, M184V | G190A | na | 0 |
| 35 | M184V | V108I, Y181C | 256 | 2,111 |
| 36 | M184V | Y181C, G190A | na | 26,041 |
| 37 | K65R | V106I, Y181C | 523 | 400 |
| 38 | K65KR | K103KN, Y181CY | 409 | na |
| 39 | M184V, T215FS | Y181C | na | 250 |
| 40 | M184V | K101E, G190A | 394 | 24,792 |
| 41 | M184V | A98G, Y181C | 620 | 13,992 |
| 42 | M184V | V108I, Y181C | 567 | 3,985 |
| 43 | A62V M184V | G190A | 1,545 | 32,362 |
| 44 | M184V | V108I, Y181C | 464 | 16,353 |
| 45 | M184V | K101EK, Y181C | 275 | 12,161 |
| 46 | M184V | V106I, Y181C | 721 | 11,199 |
| 47 | M184V | Y181C | na | 38,697 |
| 48 | M184V | Y181C | 3,341 | 10,098 |
| 49* | M184MV | K103KN | 849 | 3,783 |
| 50# | none | V106I | na | 2,582 |
| 51 | none | none | 962 | 400 |
Samples are grouped according to the WHO age classification and are listed based on the total number of reported resistance mutations. All patients were on a stavudine+amivudine+nevirapine regimen, except otherwise indicated (*), and classified as HIV-1 CRF_AE subtype, except otherwise indicated (#). Data not available are indicated (na).
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitors.